Loyal, a San Francisco, CA-based biotech company developing drugs for dogs, raised $45M in Series B funding.
The round, which brought the total amount to $125M, was led by Bain Capital Ventures, with participation from Khosla Ventures, First Round Capital, Box Group, Collaborative Fund, Quiet Capital, and Todd & Rahul’s Angel Fund.
The company intends to use the funds to support continued development with expected product launch in early 2025, pending FDA approval.
Led by CEO Celine Halioua, Loyal is a biotech startup developing drugs for dogs. By targeting the underlying mechanisms of aging, it hopes to extend the lifespan of dogs and maintain their quality of life as they age.
Loyal currently has three drugs in development. LOY-001 and LOY-003 are designed to extend the healthy lifespan of large-breed dogs, and LOY-002 is designed for senior dogs 14 pounds and over.
Commenting on the news, Celine Halioua said: “All of our work is centered on giving dogs longer, healthier lives. I’m proud of the work the team has done to date and we have a very important and challenging vision to realize. I’m excited to work with our new and existing investors and continue to make FDA-approved dog longevity drugs a reality.”
